Cervical cancer is the second most common cancer in women worldwide and the leading cause of cancer deaths in developing countries. While incidence and mortality rates of cervical cancer have fallen significantly in developed countries, 83% of all new cases that occur annually and 85% of all deaths from the disease occur in developing countries. Cervical cancer is the most common cancer among women in sub-Saharan Africa. The incidence is on the increase in some countries. Knowledge and awareness of this disease on the continent are very poor and mortality still very high. Facilities for the prevention and treatment of cervical cancer are still very inadequate in many countries in the region. Governments in sub-Saharan Africa must recognise cervical cancer as a major public health concern and allocate appropriate resources for its prevention and treatment, and for research. Indeed, cervical cancer in this region must be accorded the same priority as HIV, malaria, tuberculosis and childhood immunisations.

Gynecologic cancers pose a substantial global health challenge, disproportionately affecting women in low‐ and middle‐income countries (LMICs). Although high‐income countries (HICs) have witnessed advancements in prevention, early detection, and treatment, LMICs continue to experience elevated incidence and mortality rates, coupled with diminished survival outcomes. In 2022, these cancers accounted for approximately 1.4 million new cases and over 600 000 deaths worldwide, concentrated primarily in LMICs. This disparity stems from a confluence of systemic factors, including limited access to health care, absent or inadequate cervical cancer screening programs, underdeveloped healthcare infrastructure, and socioeconomic barriers such as poverty and lack of health insurance. Furthermore, shortages of trained specialists, advanced diagnostic tools, and effective treatment modalities hinder care delivery in resource‐constrained settings. This paper delves into the root causes of these disparities, exploring the systemic and structural obstacles impeding equitable gynecologic oncology care in LMICs. Evidence‐based recommendations will focus on expanding access to preventative measures like HPV vaccination and cervical cancer screening, enhancing timely diagnosis and treatment, and bolstering healthcare systems to address workforce and infrastructure deficits. Achieving equitable outcomes requires concerted global efforts to bridge resource gaps, prioritize health system reforms, and cultivate partnerships between HICs and LMICs for expertise and resource sharing. Ultimately, addressing these disparities is essential to ensure that all women, irrespective of geographic location or socioeconomic status, can access quality care, thereby mitigating the global burden of gynecologic cancers and improving survival.

Inflammation is pathognomonic of all stages of tumor formation, and therefore, there is renewed interest in systemic inflammatory response (SIR) markers including haematological inflammatory markers such as neutrophil-to-lymphocyte ratio (NLR) as prognostic predictors in several cancers. This study was aimed to investigate the effect of pretreatment peripheral blood NLR on the survival prognosis of patients with epithelial ovarian cancer (EOC). We identified 93 patients with a complete clinical record from a cohort of 155 patients who received treatment for EOC between 2009 and 2018. Patients’ sociodemographic and clinicopathologic characteristics, and updated three-year follow-up status were extracted from medical records. Pretreatment peripheral blood NLR was calculated by dividing the neutrophil count by the lymphocyte count. We employed the receiver operating characteristic (ROC) curve to identify the optimal cut-off value of the NLR in estimating progression-free survival (PFS) and overall survival (OS). The PFS and OS were assessed using the Kaplan-Meier method, and survival differences were compared using the Log Rank (Mantel-Cox) test. Independent prognostic predictors were determined using Cox regression analysis. According to the ROC curves, the optimal cut-off values for the NLR were 2.23 and 1.93 for PFS and OS, respectively. A high NLR was associated with poor PFS (P = 0.033) and OS (P = 0.013) in the univariate analyses. In the multivariate analyses, a high NLR was still an independent predictor of OS (hazard ratio [HR] = 2.23; 95% CI, 1.08 to 4.61) but not PFS (hazard ratio [HR] = 2.43; 95% CI, 0.95 to 6.27). The NLR at an optimum cut-off value of 1.93 is an independent prognostic predictor of OS in patients with EOC.

Vaginal cancer is rare and accounts for only 1 to 2% of all gynaecological malignancies. They arise as primary squamous cell cancers or are the result of extension from the cervix or vulva. Primary mucinous vaginal adenocarcinoma of intestinal-type is an extremely rare malignancy of unknown histogenesis with a diagnostic dilemma for the clinician and histopathologist. We presented the case of a 40-year-old Para 0⁺² woman with the complaint of a mass in the vagina and recurrent vaginal bleeding who was evaluated and worked-up for examination under anaesthesia and biopsy of the vaginal mass. The histological examination revealed the unusual intestinal-type variant of adenocarcinoma of the vagina. Recognition of this rare entity is important, particularly to avoid the pitfall of misdiagnosing metastatic disease as primary vaginal cancer.